Theratechnologiesの発行済株式数
Theratechnologiesの発行済株式数は何ですか。
Theratechnologies, Inc.の発行済株式数は95.142Mです。
発行済株式数の定義は何ですか。
発行済株式数は、投資家によって承認、発行、購入され、保有されている法人または金融資産のすべての株式である。
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
TSXのセクタHealth Careにおける発行済株式数の企業と比べるTheratechnologies
Theratechnologiesは何をしますか。
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Theratechnologiesと類似の発行済株式数
- Shriroの発行済株式数は95.088Mです。
- Lilisの発行済株式数は95.098Mです。
- Western Asset High Income Opportunity Fund Incの発行済株式数は95.099Mです。
- Monadelphousの発行済株式数は95.122Mです。
- Silver Viper Mineralsの発行済株式数は95.130Mです。
- Beijing Chunlizhengda Medical Instruments Coの発行済株式数は95.140Mです。
- Theratechnologiesの発行済株式数は95.142Mです。
- GasLog Ltdの発行済株式数は95.193Mです。
- Gainey Capitalの発行済株式数は95.196Mです。
- Nano One Materialsの発行済株式数は95.230Mです。
- Voltaliaの発行済株式数は95.244Mです。
- Lithoquest Diamondsの発行済株式数は95.244Mです。
- Prosperity Bancsharesの発行済株式数は95.261Mです。